Phaseline

Companies › Mabsoft Therapeutics (Shanghai)

Mabsoft Therapeutics (Shanghai): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Immunology; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MST-931
monoclonal antibody
–Phase 1Ankylosing Spondylitis (AS)Jul 2027
MST-168
Antibody-drug conjugate (ADC)
–Phase 1NeoplamsJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07903493MST-931Phase 1Ankylosing Spondylitis (AS)ImmunologyJul 2027
NCT07644650MST-168Phase 1NeoplamsOncologyJun 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.